Pfizer Exceeds Q3 2025 EPS Projections Despite Drop in Revenue

Financial Performance: Pfizer reported Q3 2025 revenues of $16.7 billion, a 6% decline year-over-year, primarily due to reduced COVID-19 product sales, while its non-COVID portfolio grew by 4%. The diluted EPS was $0.62, below expectations, but the adjusted EPS of $0.87 exceeded forecasts, demonstrating effective cost management.

Guidance Update: The company raised its full-year 2025 adjusted diluted EPS guidance to a range of $3.00 to $3.15, reflecting confidence in strategic initiatives and cost improvements, with a projected revenue range of $61.0 to $64.0 billion.

Cost Savings Initiatives: Pfizer aims for $7.2 billion in net cost savings by the end of 2027, which is expected to enhance productivity and operating margins, alongside a revised effective tax rate on adjusted income of approximately 11.0%.

Strategic Developments: Pfizer's ongoing business development efforts, including a proposed acquisition of Metsera and a significant agreement with the U.S. Government, are intended to strengthen its market position and support long-term growth.